MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of therapies for cancer. The Company is focused on the development of lead drug candidate, Pracinostat, which is in three Phase II clinical trials. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor that is being developed for advanced hematologic diseases such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The Company’s clinical development pipeline includes isoflavone-based mitochondrial inhibitor drug candidate, ME-344.